

BioIVT LLC and Handok Biotech sign agreement to advance innovation in South Korea

28 May 2025 | News

Focusing on drug discovery, development, toxicology, and personalised medicine expansion strategy



US-based BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, has announced an exclusive commercial agreement with Handok Biotech Co. which will allow Handok to offer researchers in South Korea access to a wider range of high-quality, innovative products. The strategic alliance provides unparalleled opportunities for researchers, ultimately, elevating life science research in Asia.

With this agreement, Handok Biotech will exclusively represent BioIVT's comprehensive portfolio of biofluids, tissues, cell products, media, and subcellular fractions/enzymes in South Korea. Access to this diverse range of biological materials is essential to drive drug discovery, development, toxicology, and personalised medicine research.

Mun-Chul Lee, CEO at Handok Biotech said, "This relationship will provide faster lead times and competitive pricing, while ensuring ongoing technical support and customer service, further enhancing the overall research experience."

Dimas Neto, Director, Global Channel Partnerships at BioIVT said, "Together, we remain dedicated to advancing scientific discoveries that have the potential to transform healthcare and improve patient outcomes worldwide."